These remain good days for Swiss drug and diagnostics giant Roche (Nasdaq:RHHBY),
as the company continues to see double-digit growth across most of its
oncology franchise, with ongoing growth in diagnostics and early signs
of additional operating leverage. While Roche's oncology pipeline looks
solid, it's well worth asking if management has been too slow to move to
bulk up other areas. Although Roche shares still look a little
undervalued, M&A speculation is likely to remain in play for the foreseeable future, likely adding volatility to the shares.
Please click here for more:
http://www.investopedia.com/stock-analysis/072913/roche-delivering-leverage-still-needs-diversification-rhhby-abt-jnj-alxn-vrtx.aspx
No comments:
Post a Comment